Humana Inc. (NYSE:HUM) Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. trimmed its position in Humana Inc. (NYSE:HUM) by 69.6% during the second quarter, HoldingsChannel.com reports. The firm owned 5,314 shares of the insurance provider’s stock after selling 12,192 shares during the quarter. Edgestream Partners L.P.’s holdings in Humana were worth $1,986,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Pzena Investment Management LLC raised its stake in shares of Humana by 538.7% in the 2nd quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock valued at $866,250,000 after acquiring an additional 1,955,375 shares during the period. Davis Selected Advisers boosted its position in shares of Humana by 16.1% in the second quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock worth $863,640,000 after buying an additional 321,233 shares during the period. Sanders Capital LLC acquired a new stake in shares of Humana in the fourth quarter valued at about $489,300,000. Ontario Teachers Pension Plan Board raised its holdings in shares of Humana by 11,647.2% during the 1st quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock valued at $367,342,000 after buying an additional 1,050,459 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Humana by 2.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,018,248 shares of the insurance provider’s stock worth $380,368,000 after acquiring an additional 20,891 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Down 1.0 %

Shares of Humana stock opened at $312.00 on Friday. Humana Inc. has a twelve month low of $298.61 and a twelve month high of $530.54. The stock has a market capitalization of $37.60 billion, a price-to-earnings ratio of 19.43, a PEG ratio of 2.56 and a beta of 0.50. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The business’s 50 day simple moving average is $359.14 and its 200-day simple moving average is $345.90.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The company had revenue of $29.54 billion for the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the business posted $8.94 earnings per share. Equities research analysts forecast that Humana Inc. will post 16 earnings per share for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.13%. The ex-dividend date is Monday, September 30th. Humana’s dividend payout ratio (DPR) is 22.04%.

Analysts Set New Price Targets

HUM has been the topic of a number of analyst reports. Oppenheimer lifted their price objective on shares of Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. Royal Bank of Canada boosted their price objective on shares of Humana from $385.00 to $400.00 and gave the stock an “outperform” rating in a report on Thursday, September 5th. Truist Financial raised their target price on Humana from $355.00 to $400.00 and gave the company a “hold” rating in a research note on Monday, July 15th. Deutsche Bank Aktiengesellschaft boosted their price target on Humana from $341.00 to $349.00 and gave the stock a “hold” rating in a research note on Friday, August 2nd. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $395.00 price objective on shares of Humana in a research note on Tuesday, September 10th. Thirteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Humana has an average rating of “Hold” and a consensus target price of $398.70.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.